Compare AIP & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIP | PAHC |
|---|---|---|
| Founded | 2003 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2021 | 2014 |
| Metric | AIP | PAHC |
|---|---|---|
| Price | $32.67 | $33.90 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | $16.83 | ★ $41.25 |
| AVG Volume (30 Days) | ★ 1.0M | 277.6K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.91% |
| EPS Growth | 4.65 | ★ 1883.33 |
| EPS | N/A | ★ 1.90 |
| Revenue | $70,579,000.00 | ★ $833,350,000.00 |
| Revenue This Year | $30.24 | $17.03 |
| Revenue Next Year | $19.50 | $3.82 |
| P/E Ratio | ★ N/A | $17.31 |
| Revenue Growth | ★ 22.27 | 4.12 |
| 52 Week Low | $8.42 | $25.58 |
| 52 Week High | $50.26 | $60.08 |
| Indicator | AIP | PAHC |
|---|---|---|
| Relative Strength Index (RSI) | 41.86 | 53.70 |
| Support Level | $31.33 | $30.46 |
| Resistance Level | $38.73 | $34.57 |
| Average True Range (ATR) | 3.31 | 1.24 |
| MACD | -1.22 | 0.45 |
| Stochastic Oscillator | 10.65 | 78.78 |
Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum its revenue from Asia Pacific.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.